This platform features China's first-in-class integrated R&D system for original small-molecule anti-metastasis drugs. It addresses the core clinical challenge of distant tumor metastasis, the root cause of 90% of cancer-related deaths. Built on self-developed comprehensive biological models, multi-dimensional target verification technologies and AI-powered intelligent drug design, the platform forms a full closed-loop R&D pipeline covering novel target identification, high-throughput compound screening, molecular druggability optimization, systematic in vitro & in vivo pharmacodynamic evaluation, and all-round patent layout.
We focus on developing innovative small-molecule drugs that broadly block tumor migration and invasion to prevent cancer metastasis and facilitate radical cure. Our candidates target high-incidence solid tumors including breast cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer and more, delivering differentiated efficacy distinct from conventional chemotherapy, targeted therapy and immunotherapy. Currently, we hold a total of 11 patents related to anti-cancer cell metastasis drugs, including both granted patents and patents under examination.
Core Technical Modules
1. Novel Target Discovery & Orthogonal Verification Module
We established a Vimentin luciferase reporter cell system based on CRISPR/Cas9, paired with six orthogonal verification techniques: Pull-down protein capture, LC-MS mass spectrometry, DARTS, CETSA, SPR surface plasmon resonance and molecular docking. These tools accurately identify novel anti-metastasis targets and validate specific drug-target interactions from multiple dimensions including protein binding, cellular thermal stability and real-time binding affinity, resolving the industry-wide pain point of insufficient credibility in target druggability verification.
2. High-Throughput Anti-Metastasis Compound Screening Module
We independently constructed highly metastatic nasopharyngeal carcinoma S18 cell strains and stable metastatic breast/lung cancer cell models, alongside a luciferase-based high-throughput screening system capable of preliminary activity screening for hundreds of compounds in a single run. Supported by in vitro functional assays including scratch wound healing and Transwell invasion tests, we rapidly screen potent anti-metastasis lead molecules at nanomolar to sub-micromolar concentrations. The platform has yielded multiple highly active candidate compounds including EH-M001, EH-M006, EH-M007 and SGI-02.
3. AI-Assisted Molecular Design & Druggability Optimization Module
Integrating AI virtual screening, target binding pocket prediction, intelligent structural modification of lead compounds and ADMET pharmacokinetic property prediction, our technology boosts R&D efficiency 100-fold compared with traditional experiments and cuts R&D cycles by 30%–50%. We conduct targeted optimization of binding affinity, metabolic stability and safety for lead molecules to generate high-activity derivatives such as EH-M006A (Z15-11B3) and EH-M007A (NCP26-1C), while filing patents for all AI-optimized novel molecules to build robust global intellectual property barriers. Furthermore, through AI-driven drug discovery and rational molecular design, we have developed a novel small-molecule candidate, SGI-02, with potential therapeutic applications in preventing and treating cancer metastasis.
4. Dedicated In Vivo Pharmacodynamic Evaluation Module for Tumor Metastasis
We have standardized spontaneous metastasis models (foot pad – popliteal lymph node) and lung metastasis animal models. In vivo fluorescence imaging quantifies metastatic burden in lymph nodes and lungs, enabling systematic evaluation of dosage gradients, metastasis incidence, median survival and synergistic effects of combination therapies. Our candidates are proven to drastically reduce the risk of distant tumor metastasis. The platform opens its animal models to external institutions for collaborative research.
Platform Pipeline Outputs
The platform has incubated multiple corepreclinical pipelines: EH-M001, EH-M002, EH-M006, EH-M007 and SGI-02 small-molecule compounds, all in the final stage of preclinical research. Multiple pipelines plan to complete IND applications and advance to Phase I/II clinical trials. Upon launch, peak annual sales are projected to reach USD 3–5 billion, serving as the company's core driver of revenue growth.
